ACS Science-to-Strategy Summit WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This symposium is designed for interventional cardiologists, cardiologists, cardiology program directors, and other healthcare providers caring for patients with acute cardiovascular disease.

Registration:

Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified symposium and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from The Medicines Company, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

A. Michael Lincoff, MD
Relationships with Industry Research Sponsors
Cleveland Clinic Cardiovascular Coordinating Center
Abraxis, Alexion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb (BMS), Cardionet, Centocor, Converge Medical Inc., Cordis, Dr. Reddy’s Laboratory, Edwards Lifesciences, Esperion, GE Medical, Genentech, Gilford, GSK, Guidant, J&J, Kensey-Nash, Lilly, Medicines Company, Medtronic, Merck, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering-Plough, Scios, St. Jude Medical, Takeda, VasoGenix, Viacor

Peter B. Berger, MD, FACC
Grant/Research Support: Conor and Cardiokinetix
Honoraria: BMS, sanofi-aventis, Schering-Plough, Lilly and Daiichi/Sankyo
Consultant: Cordis/Johnson & Johnson, Boston Scientific and Biogen
Equity: Lumen, Inc.

E. Magnus Ohman MD, FRCPI, FACC
Research Grants: Berlex, sanofi-aventis, Schering-Plough Corporation, Bristol Meyer Squibb, and Millennium. Stockholder: Medtronic. Consultant: Response Biomedical, Liposcience, and Inovise Medical

Elliott M. Antman, MD, FACC, FAHA
Grant/Research Support: sanofi-aventis, Eli Lilly
Consultant: Eli Lilly

Program Faculty:

A. Michael Lincoff, MD
Vice Chairman for Research
Department of Cardiovascular Medicine
Director, Cleveland Clinic Cardiovascular Coordinating Center
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve UniversityThe Cleveland Clinic Foundation
Cleveland, Ohio

Peter B. Berger, MD, FACC
Associate Chief for Clinical Research
Geisinger Hospitals and Clinics
Danville, Pennsylvania

E. Magnus Ohman MD, FRCPI, FACC
Professor of Medicine
Director, Program for Advanced Coronary Disease
Division of Cardiology
Duke University Medical Center
Durham, NC

Elliott M. Antman, MD, FACC, FAHA
Professor of Medicine
Harvard Medical School
Director of the Coronary Care Unit (CCU)
Brigham and Women’s Hospital
Boston, MA

Educational Objectives:

As a result of this session, cardiologists and related specialists will be able to assess and implement optimal antithrombotic strategies for patients with acute coronary syndromes (ACS).
As a result of this session, attendees will understand the impact of specific pharmacologic agents on outcomes, including ischemic endpoints, bleeding, and mortality for patients with ACS.
As a result of this session, attendees will be able to discuss the impact that new trials are likely to have on future management of patients with ACS.
As a result of this session, attendees will learn to apply AHA/ACC/SCAI and other national guidelines in order to optimize therapy ACS.

Disclaimer:

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

YES, I have read the CME information statement


Key Program Topics Include: Abciximab ACC/AHA ACS ACUITY Acute Coronary Syndromes Adenosine Albumin Anticoagulants Anticoagulation Antiplatelet SYNERGY Aspirin Bivalirudin Bleeding Cath Lab Catheterization Streams CLARITY–TIMI 28 Class I	Class IIa Class IIb Class III Clopidogrel CPK-MB CREDO CRUSADE Double-bolus t-PA Early Invasive Early Invasive Therapy Echocardiogram Emergency Department enoxaparin Eptifibatide EXTRACT Fibrinolysis Fibrinolytics Fondaparinux GIK GP IIb/IIIa GP IIb/IIIa inhibition GP IIb/IIIa Inhibitors	Guidelines Classes of Recommendations GUSTO Hirudin Initial Conservative Initial Conservative Therapy ischemic LMWH low-molecular-weight heparin lytic Magnesium MI Myocardial Infarction Myoglobin Net Clinical Benefit nPA NSTE ACS Risk Stratify Chest Pain NSTEMI	PCI OASIS-5 Oral GP IIb/IIIa Parenteral Antiplatelet Therapy Pexulizamab Primary End Point PSGL REPLACE 2 Revascularization rPA STEMI SYNERGY Thienopyridine TIMI TIMI 25 Tirofiban TNK Troponin UA UA/NSTEMI UFH unfractionated heparin Unstable Angina Upstream